Abbott logo

AbbottABT

NYSE

Pharmaceuticals

$103.00-1.03%

AI Multi-Horizon Analysis

Short-term45% confidence
Neutral

Limited technical data; price below recent insider sales at $116 suggests near-term defensiveness. Momentum unquantifiable without intraday candles.

Mid-term50% confidence
Bearish

Margin contraction, rising debt, cash drawdown, and net insider selling bias likely to weigh on price over days to weeks. FCF strength provides partial offset.

Long-term50% confidence
Neutral

FCF momentum and diversified healthcare portfolio support resilience, but persistent margin pressure, elevated leverage, and liquidity trends introduce risk of multiple compression.

Overall AI View55% confidence
Neutral

Mixed fundamental picture with strong sequential FCF growth offset by contracting margins, sharply higher leverage, declining liquidity, and net insider selling. Near-term supply pressure likely; longer-term trajectory depends on margin stabilization and debt deployment.

Detailed AI Fundamental Analysis

Business Snapshot

Abbott Laboratories (ABT) is a diversified global healthcare company primarily engaged in the development, manufacture, and sale of pharmaceutical preparations, diagnostic products, medical devices, and nutritional products. With approximately 115,000 employees and a market capitalization of roughly $190.2 billion, ABT trades as common stock on the NYSE under the ticker ABT. The company has been publicly listed since 1949 and maintains a broad portfolio spanning established pharmaceuticals, cardiovascular devices, diabetes care (including Freestyle Libre), structural heart solutions, and core laboratory diagnostics. Its business model emphasizes recurring revenue from consumables, diagnostics, and chronic-care devices, providing relative stability compared to pure-play pharmaceutical peers.

Financial Trends

Revenue shows clear sequential acceleration across the reported quarters: Q3 2026 revenue rose 3.3% to $13.013 billion from $12.593 billion in Q2 2026, which itself represented a 12.8% increase from $11.164 billion in Q1 2026. Full-year 2025 revenue stood at $44.328 billion, establishing a baseline for the 2026 quarterly ramp.

Operating margins have been volatile and generally contracting from the prior-year base: operating margin fell to 10.44% in Q3 2026 from 13.44% in Q2 2026 and 12.05% in Q1 2026, versus a much higher 18.17% for full-year 2025. Net margins followed a similar decelerating path, declining to 7.07% in Q3 2026 from 7.37% in Q2 and 9.65% in Q1, compared with 14.72% for full-year 2025.

Free cash flow demonstrates strong sequential improvement: Q3 2026 FCF reached $4.131 billion, up 42.1% from $2.907 billion in Q2 2026 and more than 4.5× the $0.916 billion recorded in Q1 2026. This compares against full-year 2025 FCF of $7.395 billion, indicating robust cash conversion in the most recent quarter despite margin pressure.

Balance-sheet strength has deteriorated on several fronts. Total assets contracted sequentially from $110.429 billion at end-Q1 2026 to $108.247 billion at end-Q3 2026. Shareholders’ equity declined steadily from $52.130 billion at end-2025 to $51.027 billion at end-Q3 2026. Cash & equivalents fell sharply from $8.522 billion at year-end 2025 to $4.052 billion by Q3 2026. Long-term debt jumped dramatically from $9.896 billion at end-2025 to approximately $29.5 billion across the first three quarters of 2026, driving the Debt/Equity ratio from 0.19 to 0.58. Current ratio weakened from 1.58 at year-end 2025 to 1.45 at Q3 2026, while working capital declined from $9.5 billion to $7.344 billion over the same span. Inventory has risen steadily from $6.488 billion at end-2025 to $7.337 billion at Q3 2026.

Financial Health

The latest Q3 2026 results reflect a company that continues to generate solid operating cash flow and improving free-cash-flow momentum, yet faces mounting pressure from margin compression, rising leverage, and a shrinking cash balance. The sharp increase in long-term debt (nearly tripling year-over-year) combined with sequential declines in total assets, equity, and cash suggests a period of elevated capital deployment or acquisition activity that has altered the capital structure. While the current ratio of 1.45 remains adequate and working capital is still positive, the trajectory of declining liquidity metrics and higher interest-bearing obligations increases balance-sheet risk relative to the more conservative posture at year-end 2025. Continued FCF strength provides a buffer, but sustained margin erosion could limit flexibility if macroeconomic or industry-specific headwinds intensify.

Insider Activity

Insider sentiment over the August–November 2026 window is Neutral with a net selling bias of –$31.05 million. Across 18 disclosed transactions, insiders executed $21.72 million in buys against $52.77 million in sells. The most recent filing on 2026-11-06 shows EVP Mary K. Moreland selling 3,500 common shares at $116.00 for total proceeds of $406,000. The preponderance of selling activity, particularly at prices above the current $110.17 level, indicates cautious positioning by corporate insiders despite the neutral aggregate sentiment score.

Multi-Timeframe Technical Context

With the active timeframe labeled “fundamental” and limited intraday or multi-horizon candle data supplied, technical context is constrained. The current price of $110.165 sits materially below the most recent insider sales executed at $116, suggesting near-term supply pressure or profit-taking. Absent explicit 1-minute through daily OHLC and indicator values, momentum, volatility, and moving-average alignment cannot be quantified; however, the combination of recent insider distribution and the observed contraction in cash and equity on the balance sheet implies potential for defensive price action in the hours-to-days horizon. Over longer weekly-to-monthly periods, the stock’s valuation will likely be anchored to the trajectory of FCF growth versus the elevated debt load and margin trends.

Bull / Bear Cases

Short-term (hours to days):
Bull case: Continued acceleration in quarterly revenue and the sharp sequential rebound in FCF could catalyze a relief rally if upcoming data releases or sector flows reinforce confidence in operational momentum, potentially filling toward the $116 insider-sale level.
Bear case: Persistent net insider selling, combined with the latest margin contraction and liquidity drawdown, may trigger further near-term selling pressure, especially if broader market sentiment turns risk-off.

Long-term (weeks to months):
Bull case: Sustained FCF generation above $4 billion per quarter, coupled with any stabilization in operating margins or successful deployment of the elevated debt into high-return acquisitions or R&D, could support multiple expansion and a re-rating as a resilient healthcare compounder.
Bear case: If margin erosion persists, debt remains elevated, and cash balances continue to decline, investors may discount the equity for higher leverage risk and slower earnings quality, capping upside and potentially retesting lower valuation ranges seen prior to the 2026 capital-structure shift.

Key Levels & Triggers

  • Immediate resistance: $116.00 (recent insider-sale execution price).
  • Psychological/round-number support: $110.00 and $105.00.
  • Fundamental trigger (positive): Sequential improvement in operating margin above 13% or sustained FCF > $3.5 billion per quarter.
  • Fundamental trigger (negative): Further increase in Debt/Equity above 0.60 or continued rapid drawdown in cash & equivalents below $4 billion.
  • Insider-flow trigger: Any acceleration in net selling or a shift back toward net buying in forthcoming Form 4 filings.
  • Liquidity trigger: Rebound in current ratio above 1.55 or stabilization of working capital near $9 billion would signal balance-sheet repair.

Financials

From SEC EDGAR · Period 2026-09-30 · Source form 10-Q

Income Statement · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-K
Revenue$13.01B$12.59B$11.16B$44.33B
Operating Income$1.36B$1.69B$1.34B$8.05B
Net Income$920.00M$928.00M$1.08B$6.52B
EPS (Diluted)$0.53$0.53$0.61$3.72
Operating Margin10.44%13.44%12.05%18.17%
Net Margin7.07%7.37%9.65%14.72%

Balance Sheet · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-Q
Total Assets$108.25B$109.22B$110.43B$86.71B
Shareholders' Equity$51.03B$51.11B$52.06B$52.13B
Cash & Equivalents$4.05B$5.10B$6.80B$8.52B
Long-term Debt$29.45B$29.60B$29.64B$9.90B
Current Ratio1.451.381.391.58
Debt / Equity0.580.580.570.19

Cash Flow · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-K
Cash from Operations$5.54B$3.80B$1.31B$9.57B
Cash from Investing-$21.38B-$21.00B-$20.32B-$2.42B
Cash from Financing$11.39B$13.79B$17.31B-$6.31B
Capital Expenditures$1.41B$896.00M$399.00M$2.17B
Free Cash Flow$4.13B$2.91B$916.00M$7.39B

Income Statement

Revenue
$36.77B
Gross Profit
$4.40B
Operating Income
$4.40B
Net Income
$2.92B
EPS (Basic)
$1.67
EPS (Diluted)
$1.67

Balance Sheet

Total Assets
$108.25B
Total Liabilities
—
Shareholders' Equity
$51.03B
Cash & Equivalents
$7.63B
Long-term Debt
$29.45B
Shares Outstanding
1.73B

Cash Flow

Cash from Operations
$5.54B
Cash from Investing
-$21.38B
Cash from Financing
$11.39B
Capital Expenditures
$1.41B
Free Cash Flow
$4.13B

Key Ratios

Gross Margin
11.96%
Operating Margin
11.96%
Net Margin
7.95%
Current Ratio
1.45
Debt / Equity
0.58
Free Cash Flow
$4.13B

Insider Activity

1 insider filings (2026-10-10 to 2026-11-09) — sourced directly from SEC Forms 4/5

Buys
$0.00 · 0
Sells
$406.0K · 1
Net
-$406.0K
Filings Parsed
1
Trade DateInsiderActionSharesPriceValue
2026-11-05Moreland Mary KSell3,500$116.00$406.0K

Key Stats

$178.23BMarket cap
$139.0652-week high
$90.7252-week low
13,625,527Avg volume (30d)

115,000 employees1.73B shares outstandinglisted 1949-04-19dividend yield 2.69%

Next earnings ~May 5, 2026 · Ex-dividend Apr 15, 2026 · Dividend $0.63 quarterly

About Abbott

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

Latest News

ABT catalysts

We track ABT on Sector Watch from primary sources. See its FDA dates, trials and filings

Related Stocksin Pharmaceuticals

Related research

More in Market history

Ready to see the live AI view on ABT?

Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing ABT side-by-side with live signals.